Ipca Laboratories Ltd. and Bhami’s Research Laboratory (BRL) have entered into a definitive global licensing agreement that will enable the development and commercialization of multiple monoclonal antibody products for oncology and inflammatory diseases using BRL’s proprietary high-concentration subcutaneous biologics delivery platform.

Under the agreement, Ipca will gain access to BRL’s patented formulation technology, which is designed to facilitate the subcutaneous delivery of biologic therapies. 

The collaboration aims to develop differentiated biologics that offer greater convenience and accessibility for patients while expanding treatment options in cancer and autoimmune diseases.

As part of the partnership, BRL will undertake proof-of-concept and formulation development activities. Ipca will be responsible for further research and development, clinical trials, regulatory activities, and commercialization of the products globally.

BRL will receive defined milestone payments related to technology transfer and will also earn royalties on net sales following the commercialization of the products.

Pranay Godha, Managing Director and CEO of Ipca Laboratories, said, “By pairing Ipca’s established science with BRL’s Novel Formulation Platform, we’re accelerating developing affordable biologics for people battling cancer and autoimmune disease worldwide.”

Dr. Suryakanth M. Pai, Co-founder and CEO of BRL, said, “We are delighted to be expanding the reach of our novel, proprietary, patented subcutaneous protein delivery platform technology through this exciting partnership with Ipca to develop differentiated biologics for the global market. This strategic partnership is designed to make patient care convenient, affordable and safe.”

The transaction was supported by WeTranslate, a commercialization and strategic advisory firm.

“BRL has built a differentiated formulation technology platform, and Ipca brings the scale, expertise, and global reach required to unlock its full potential. We are delighted to support this collaboration and look forward to seeing its impact on the future of biologic drug delivery,” said Akhil Shah, Director and CEO of WeTranslate.